Blog
Using CANTAB to develop AI-based tools for the early detection of dementia
To mark World Alzheimer's Day, we hear from Christoffer Hatlestad-Hall and his team at Oslo University Hospital, who explain how CANTABTM is an instrumental part of their study using AI and machine learning to identify the earliest signs of Alzheimer's and dementia in people with mild cognitive impairment.
Targeting adolescent neurocognitive processes in depression to promote intervention response
Florin Tibu from the Department of Health and Human Development at the Stefan cel Mare University of Suceava recently gave us an insight into how CANTAB has impacted his research into targeting adolescent neurocognitive processes in depression to promote intervention response.
Using CANTAB to understand the role of cognitive control and rumination in predicting depression amo
We recently caught up with Sanja Jandric, from the University of Osijek to discuss her research into the role of cognitive control and rumination in predicting depression among adolescents with internalising disorders.
Using CANTAB to compare the effects of augmented reality N-back training and traditional two-dimensi
We recently caught up with Dr Bo Zhang from East China Normal University to discuss her research: A Comparison of the Effects of Augmented Reality N-Back Training and Traditional Two-Dimensional N-Back Training on Working Memory
Acoustic features of voice as a measure of cognitive load during performance of serial subtraction i
Director of Research & Innovation, Francesca Cormack, presented acoustic features of voice as a measure of cognitive load during performance of serial subtraction in a remote data collection context at AAIC 2021.
Read on for the key findings and full poster.
Feasibility of Repeated Administration of Automated Verbal-Paired-Associate Memory in Older Adults
At AAIC 2021, Alex Kaula - R&D Scientist, hosted an interactive poster session on: Feasibility of Repeated Administration of Automated Verbal-Paired-Associate Memory in Older Adults
Read on for the key findings and full poster.
CANTAB Research Grant funds new ways to assess vascular cognitive impairment and dementia (VCID) in
Dr Simone De Luca recently received the 2020 CANTAB Research Grant primary award for her project: “New ways to assess vascular cognitive impairment and dementia (VCID) in chronic lung disease”. We spoke to her about the impact winning would have on her research.
6 tests for assessing cognition in Parkinson’s disease
Cognitive dysfunction in Parkinson’s disease remains a significant, unmet therapeutic need for patients; as such it is vital that there is rigorous research into the topic. Here we will discuss six CANTAB tasks that can address this research gap.
Exploring participant-level trajectories of cognitive performance in patients with schizophrenia
Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.
What does the new FDA guidance mean for clinical trials in early Alzheimer’s disease?
The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development.
Can acetylcholinesterase inhibitors and CNS stimulants tackle cognitive dysfunction in multiple scle
Cognitive dysfunction in multiple sclerosis (MS) presents a significant, unmet therapeutic need. Researchers at Cambridge Cognition and the University of Manchester investigated potential solutions to this problem with a systematic review and meta-analysis of pro-cognitive drug trials in MS.
How to select sensitive outcome measures in pro-cognitive drug trials for schizophrenia
The outcome measure selected for a pro-cognitive drug trial in schizophrenia must be sensitive enough to detect potentially subtle changes in cognition.
Trial design: 4 ways to improve trials of pro-cognitive drugs in schizophrenia
Discussing the methodological considerations, and suggesting recommendations, for successful pro-cognitive drugs trials in schizophrenia.
Patient recruitment: are you selecting the right patients for schizophrenia clinical trials?
The importance of recruiting patients for pro-cognitive drug trials in schizophrenia on the basis of cognitive dysfunction.
Improving clinical trials for pro-cognitive drugs in schizophrenia
Introducing a blog-post series to discuss key limitations, and potential improvements, for pro-cognitive drug trials in schizophrenia.
WEBINAR: Overcoming methodological challenges to enhance study success in schizophrenia trials
Dr Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr Steve Brannan, Chief Medical Officer, Karuna Pharmaceuticals Inc. hosted a webinar on how to improve clinical trial success in schizophrenia.
